

## Supplementary Tables

## **Supplementary Table 1: Bacterial Strains and Plasmids Used in This Study**

Name	Relevant Features	Source/Reference
<b><u>Bacterial strains:</u></b>		
<b><u>Escherichia coli</u></b>		
DH5α	F- <i>endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG purB20</i> φ80d/ <i>lacZΔM15 Δ(lacZYA-argF)U169</i> , <i>hsdR17(rK-mK+)</i> , λ-	Laboratory collection
MG1655		
Top10	F- <i>mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 Δ lacX74 recA1 araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG</i>	ThermoFisher
RFP	Top10 (pTOPO::rfp), strain 8186	Laboratory collection
XL2blue	<i>endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44</i> F'[:Tn10 proAB+ lacIq Δ(lacZ)M15 Amy CmR] <i>hsdR17(rK-mK+)</i>	Stratagene
SXT	HW220 (CAG18439 <i>pfrC::SXT</i> )	V. Burrus
β3914	β2163 [(F-) RP4-2-Tc::Mu Δ <i>adapA::(erm-pir116)</i> ] <i>gyrA462 zei-298::Tn10</i>	(1)
Π1	DH5α <i>ΔthyA::(erm-pir116)</i>	(2)
<b><u>Vibrio cholerae</u></b>		
<i>Vibrio cholerae</i> O1	<i>Vibrio cholerae</i> serotype O1 biotype El Tor strain N19691 (contains a frame shift into <i>lacZ</i> gene)	(3)
Δ <i>lacZ</i>	<i>Vibrio cholerae</i> O1- Δ <i>lacZ</i>	(4)
Δ <i>toxRS</i>	<i>Vibrio cholerae</i> O1- Δ <i>toxRS</i>	This study
O1-GFP	<i>Vibrio cholerae</i> O1- constitutive expression of <i>gfp</i>	Laboratory collection
O139	MO10 toxigenic 1992 clinical isolate from India, SXT <sup>MO10+</sup> , Su <sup>R</sup> Tm <sup>R</sup> Cm <sup>R</sup> Sm <sup>R</sup>	(5)
<b><u>Other strains</u></b>		
<i>Vibrio vulnificus</i>	WT	Laboratory collection
<i>Vibrio mimicus</i>	WT	Laboratory collection
<i>Salmonella typhimurium</i>	WT	J.M. Ghigo
<i>Citrobacter rodentium</i>	WT	J.M. Ghigo
<b><u>Plasmids:</u></b>		
pBAD43	ori pSC101, Sp <sup>R</sup>	(6)
pBAD30	ori pACYC184, Carb <sup>R</sup>	(6)
pBAD24	ori pBR322, Carb <sup>R</sup>	(6)
pSU38	ori p15A, Kan <sup>R</sup>	(7)
pSW7848	suicide plasmid for allele exchange - <i>oriV<sub>R6K</sub></i> , <i>oriT<sub>RP4</sub></i> <i>araC-P<sub>BAD</sub>-ccdB</i>	(4)
pRFP	<i>rfp</i> gene cloned in pTOPO	Laboratory collection

46

47 **Supplementary Table 1: (continuation)**

	Name	Relevant Features	Source/Reference
48	pTox	pBAD43-ccdB (between EcoRI-XbaI)	This study
49	pToxInt	pBAD43-ccdB/intein operon (between EcoRI-XbaI)	This study
50	pN	pBAD43-ccdB/intein N-terminal fusion (between EcoRI-XbaI)	This study
51	pCcdB-Int C	pSU38-ccdB/intein C-terminal fusion (between EcoRI-XbaI)	This study
52	pParE2-Int N	pBAD43-parE2/intein N-terminal fusion (between EcoRI-XbaI)	This study
53	pParE2-Int C	pSU38-parE2/intein C-terminal fusion (between EcoRI-XbaI)	This study
54	pHigB2-Int N	pBAD43-higB2/intein N-terminal fusion (between EcoRI-XbaI)	This study
55	pHigB2-Int C	pSU38-higB2/intein C-terminal fusion (between EcoRI-XbaI)	This study
56	pRelE4-Int N-1	pBAD43-relE4/intein N-terminal-1 fusion (between EcoRI-XbaI)	This study
57	pRelE4-Int C-1	pSU38-relE4/intein C-terminal-1 fusion (between EcoRI-XbaI)	This study
58	pRelE4-Int N-2	pBAD43-relE4/intein N-terminal-2 fusion (between EcoRI-XbaI)	This study
59	pRelE4-Int C-2	pSU38-RelE4/intein C-terminal-2 fusion (between EcoRI-XbaI)	This study
60	pCcdB-Int n*	pN with a mutation that blocks intein splicing	This study
61	pParE2-Int n*	pParE2-Int N with a mutation that blocks intein splicing	This study
62	pHigB2-Int n*	pHigB2-Int N with a mutation that blocks intein splicing	This study
63	pRelE4-Int n*-1	pRelE4-Int N-1 with a mutation that blocks intein splicing	This study
64	pRelE4-Int n*-2	pRelE4-Int N-2 with a mutation that blocks intein splicing	This study
65	pU-BAD	pBAD43-ccdB/int N-fusion ( <i>ompU-1</i> promoter), C-fusion under P <sub>BAD</sub>	This study
66	pRS	<i>toxRS</i> operon from <i>V. cholerae</i> cloned into pBAD30 (Sacl-XbaI) keeping natural RBS sequence of <i>toxR</i>	This study
67	pN <sub>ctrl</sub>	ori pSC101, Sp <sup>R</sup> , ccdB-Int N-terminal fusion (P <sub>ompU</sub> ), oriT <sub>RP4</sub>	This study
68	ptox <sub>ctrl</sub>	ori pSC101, Sp <sup>R</sup> , ccdB-Int N- and C-fusion (operon- P <sub>BAD</sub> ), oriT <sub>RP4</sub>	This study
69	pPW	ori pSC101, Sp <sup>R</sup> , ccdB-Int N- and C-fusion (operon- <i>ompU-1</i> promoter) oriT <sub>RP4</sub>	This study
70	ptoxRS-UP-DOW	pSW7848-500bp upstream and downstream of <i>toxRS</i> operon	This study
71	pccdA	ori pBR322, Carb <sup>R</sup> , ccdA antitoxin (P <sub>BAD</sub> )	This study
72	pPW(RBS)	pPW with canonical RBS sequence	This study
73	pPLA	pCcdBInt, ccdA (PL promoter)	This study
74	pABRW	pCcdBInt, ccdA (PL promoter), oriT <sub>RP4</sub>	This study
75	pFW	pFW1, canonical RBS in <i>ompU-1</i> promoter, extra operator O1-sequence into PL promoter	This study
76	pPW-R6K	pPW with an R6K replication origin	This study
77	pN <sub>ctrl</sub> -R6K	pN <sub>ctrl</sub> with an R6K replication origin	This study
78	pFW-R6K	pDW with an R6K replication origin	This study

86

87

88 **Supplementary Table 2.** Conjugation efficiency in the different conditions and strains used.  
 89 Conjugation efficiency is calculated as the number of transconjugants divided by the total  
 90 bacteria and multiplied by 100 to obtain the percentage (%). We have also analyzed the  
 91 conjugation of the pFW plasmid in MG1655 bacteria using a donor:recipient ratio of 1:1 and  
 92 obtaining more than 70% of conjugation efficiency.

Donor	Recipient	Figure	Donor::recipient, conditions	Total CFU/ml	Transconjugants (CFU/ml)	Efficiency (%)
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139	-	1:1, without DAP	$3.4 \cdot 10^8$	$2.4 \cdot 10^7$	7 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139	-	1:1, with DAP	$2.9 \cdot 10^8$	$2.7 \cdot 10^7$	9.3 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139	-	10:1, water	$1.8 \cdot 10^6$	$5.6 \cdot 10^2$	0.03 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O1	-	1:1	$1.3 \cdot 10^8$	$8.2 \cdot 10^6$	6.3 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O1	-	2:1	$1.3 \cdot 10^8$	$5.4 \cdot 10^6$	4.2 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O1	-	3:1	$1.2 \cdot 10^8$	$3.8 \cdot 10^6$	3.16 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139	-	1:1	$1.8 \cdot 10^8$	$7.8 \cdot 10^6$	4.3 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139	-	2:1	$1.3 \cdot 10^8$	$8.1 \cdot 10^6$	6.2 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139	-	(3:1)	$0.9 \cdot 10^8$	$8.5 \cdot 10^6$	9.4%
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139	Fig. 4a	1000:1, zebrafish	$8 \cdot 10^5$	57.5	0.0071 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139+O1	Fig. 4a	10:1, zebrafish	$7 \cdot 10^5$	200	0.025 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139	Fig. 4b	1:1, <i>Artemia</i>	$16.5 \cdot 10^6$	2170	0.013 %
$\beta$ 3914-pN <sub>control</sub>	<i>V. cholerae</i> O139+O1	Fig. 4b	1:1, <i>Artemia</i>	$16.7 \cdot 10^6$	3465	0.020 %
$\beta$ 3914-pFW	MG1655	-	1:1	$20 \cdot 10^6$	$14.7 \cdot 10^6$	72.26 %
$\beta$ 3914-pABRW	MG1655	-	10:1	$3.2 \cdot 10^5$	$2.8 \cdot 10^5$	89.58 %

93

94

95

96

97

98

99 **Supplementary Table 3. Escape mutants obtained after the conjugation of the genetic  
100 weapon plasmids in this study.** We performed conjugation with the weapon plasmids in  
101 the targeted bacteria. After conjugation, bacteria were spread in the presence of  
102 spectinomycin in order to detect transconjugants that are able to survive after the acquisition  
103 of the plasmid weapon. Numbers on the table indicate the CFU/ml of transconjugants that  
104 are named: escape mutants, for each weapon plasmid/strain in comparison with the total  
105 bacteria after conjugation.

106

Strains	Weapons		Plasmids	
	pPW	pPW <sub>(RBS)</sub>	pABRW	pFW
<i>V. cholerae</i> O1	6-log <sub>10</sub> (n=4)	7-8-log <sub>10</sub> (n=6)	-	-
<i>V. cholerae</i> O139	6-log <sub>10</sub> (n=4)	7-8-log <sub>10</sub> (n=6)	6-log <sub>10</sub> (n=5)	6-log <sub>10</sub> (n=7)
<i>E. coli</i> - SXT	-	-	5-log <sub>10</sub> (n=7)	-

107

108

109 **Supplementary Table 4. Escape mutants analyzed in this study.** We analyzed by PCR  
110 the *V. cholerae* escape mutants that survived plasmid acquisition through conjugation.  
111 Plasmids used are indicated in parentheses and numbers indicate the number of analyzed  
112 clones. The inactivating insertion sequence identified by sequencing as *V. cholerae* DNA  
113 116-17a plasmid seq. ID: LN831185. PCR products which size corresponds with the control  
114 fragment (toxin-intein amplification) were sent for sequencing and point mutations avoiding  
115 the correct translation of the toxin were detected for pPW clones. However for pFW clones,  
116 no mutations were detected after sequencing. We then transformed *V. cholerae* serogroups  
117 O1 and O139 with these plasmids that looks as pFW. The result showed that transformants  
118 were only obtained in O1 serogroup. Then these plasmids are still toxic for *V. cholerae* O139  
119 and fully able to be transferred in O1 serogroup. In order to know why these *V. cholerae*  
120 O139 clones are able to tolerate the conjugation of pFW we performed PCR to analyze the  
121 presence of *toxRS* and *setR*. After this analysis *toxRS* was correctly amplified but not *setR*.  
122 Then we demonstrated that they have lost the SXT element (see suppl. Table 4).  
123

Clones	<i>V. cholerae</i> O1 (pPW)	<i>V. cholerae</i> O139 (pPW)	<i>V. cholerae</i> O139 (pFW)	Frequency (%)
Correct toxin amplification	5	6	11	47.8 %
<i>Vibrio's Insertion Sequence</i>	6	10	5	46.67 %
No amplification	3	0	0	6.67 %
Total	14	16	16	100 %

124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140

141

142  
143  
144

145 **Supplementary Table 5. Escape mutants that lost SXT element.** Number indicated clones  
146 analyzed in MH media containing trimethoprim, which is one of the antibiotic resistant, genes  
147 encoded into SXT element.

148  
149

Clones	<i>E. coli</i> –SXT (pABRW)	Frequency (%)	<i>V. choerae</i> O139 (pFW)	Frequency (%)
Containing SXT	8	37 %	4	10 %
Lost of SXT	15	63 %	36	90 %
Total	23	100 %	40	100 %

150  
151  
152

153 **Supplementary Table 6: Primers used in this study**

	Name	Sequence (5' → 3')
154		
155	F-CcdB-EcoRI	<u>GGAATT</u> CATGTCTCAATTACGCTATAAAA
156	R-CcdB-XbaI	<u>GCTCTAGA</u> GCAAGCGTTAAATGCCAGTGATTA
157	F-Int/dB	TAAGAAATGTTAACGCTATGAAACGGAAATA
158	R-dB/Int	CTTAAACATTCTTATCAAGTAGTCGATTGG
159	R-Int-XbaI	<u>GCTCTAGA</u> TCAATTCCGGCAAATTATCAACC
160	F-Int-EcoRI	<u>GGAATT</u> CGTAAGGAGGTAACATATGATCAAATAGCCACACGTAAA
161	R-Int C/cdb-2	CTTGGTGCATTGAAACAATTAGAAGCTATGA
162	F-CcdB-C/Int 2	TTCAATGCACCAAGTCACCTTGTCC
163	F-ParE2-EcoRI	<u>GGAATT</u> CAATGAAACCATTAATCTTACCGTCGC
164	R-ParE2-XbaI	<u>GCTCTAGA</u> TTATGCGCCGAATATTGGGTCACATC
165	F-ParE2/Int-1	TTTCAATATTGGTAAATCATGCGATGAAATCCGAG
166	R-ParE2/Int-1	CTTAAACAGTCGGGATTTCCGCTAAAAGCCA
167	F-Int/ParE2-1	ATCCGACTGTTAACGCTATGAAACGGAAATA
168	R-Int/ParE2-1	TTACCAATATTGAAACAATTAGAAGCTATGAAGC
169	F-HigB2-EcoRI	<u>GGAATT</u> CGATGAAAAGTGTTAGCTGAATCAAC
170	R-HigB2/Int-1	CTTAAACACTTTCATCGAGAAAGTAATAG
171	F-HigB2/Int-1	TTTCAATAGGCCTTCTATTTGCTAAC
172	R-HigB2-XbaI	<u>GCTCTAGA</u> TATCACGATTGCTCATTGCGCCACGCC
173	F-Int/HigB2-1	GATGAAAAGTGTTAACGCTATGAAACGGAAATA
174	R-Int/HigB2-1	GAAACGCCTATTGAAACAATTAGAAGCTATGAAGC
175	F-RelE4-EcoRI	<u>GGAATT</u> CGATGATTTCGGGAAAGCATCTCAATG
176	R-RelE4/Int-1	CTTAAACAATCACGCTAACACCGATTAG
177	F-RelE4/Int-1	TTTCAATGGCATTAGAGGCAGATTGC
178	R-RelE4-XbaI	<u>GCTCTAGA</u> TCACTCGTTGGAAATTGGATGATGTAG
179	F-Int/RelE4-1	CAGCGTGATTGTTAACGCTATGAAACGGAAATA
180	R-Int/RelE4-1	CTAATGCCATTGAAACAATTAGAAGCTATGAAGC
181	R-RelE4/Int-2	CTTAAACAAATCAACCCAAATCGAAACAATC
182	F-RelE4/Int-2	TTTCAATGGTTCTAAAATTGAAATAATGCGTG
183	F-Int/RelE4-2	GGGTTGATTGTTAACGCTATGAAACGGAAATA
184	R-Int/RelE4-2	TAGAACCAATTGAAACAATTAGAAGCTATGAAGC
185		
186	R-Int/dB N mut	CCTTCCCATTCTTATCAAGTAGTCGATTGG
187	F-Int/dB N mut	TAAGAAATGGGAAAGGTATGAAACGGAAATA
188	F-Int/E4-1 N mut	GCGTGATTGGGAAAGGTATGAAACGGAAATA
189	F-Int/E4-2 N mut	GGGTTGATTGGGAAAGGTATGAAACGGAAATA
190	R-Int/E4-1 N mut	CCTTCCCATTACGCTAACACCGATTAG
191	R-Int/E4-2 N mut	CCTTCCCATTACGCTAACACCAATACGAAACAATCATTG
192	F-Int/B2 N mut	GATGAAAAGTGGGAAAGGTATGAAACGGAAATA
193	F-Int/E2 N mut	AATCCGACTGGGAAAGGTATGAAACGGAAATA
194	R-Int/B2 N mut	CCTTCCCATTTCATCGAGAAAGTAATAG
195	R-Int/E2 N mut	CCTTCCCAGTCGGATTTCGCTAAAAGCC
196		
197	R-BAD43-BAD18	CGCCACAGGCAAGGCAGTTAAGTGGTAACGCCAGG
198	F-BAD43-BAD18	CAACTATGGATTGATAAGCAGCATGCCCTGTTTC
199	R-BAD18-BAD43	ATCGAATCCATAGTTGCCTGACTCCCCGTCGTGTAG
200	F-BAD18-BAD43	ATGCCCTGCCTGTCGGCGCCGGTATGCCGCCACG
201	4216	TATCAGGGACTGGAAAATCAGAGGGCAGGAACGTG
202	4217	TCCAGTCCCTGATATAGGCGCCAGCAACCGCACC
203		
204	R-Int-N/Int-C	ACCTCCTTATCAATTCCGGAAATTATCAACCCGCATC
205	F-Int-C/Int-N	CCGAATTGATAAGGAGGTAACATATGATCAAATAGCCACAC
206		
207		
208		
209		
210		

211 **Supplementary Table 6: (continuation)**

	Name	Sequence (5' → 3')
212		
213	F-toxR-Sacl	GGGAGCTCGTCCTCAAAAGAGATATCGATGAGTCATATTGG
214	R-toxS-XbaI	GCT <u>CTAG</u> ACCTTAAGAATTACTGAACAGTACGGTAGAACCATGAC
215		
216	R-BAD-PU1	GATTTAGGTTGGTAACGAATCAGACAATTGACGGC
217	F-PompU-1	TACCAACCTAAATCGGGTCGGGTTAGGGTTGAACCATT
218	R-PompU-dB	TTGAGACATAAATTGATTTGTGCGACGTAAGCC
219	F-dB-PompU	CAAATTATGTCCTCAATTACGCTATATAAAAAC
220		
221	F-ccdA-EcoRI	<u>GGAATT</u> CACCATGAGAAATCAATATAACACAAGCGTAAAGAAAGC
222	R-ccdA-XbaI	GCT <u>CTAG</u> ATTAAAATACTCGGTATGAATCAGAAAAAGACCGTG
223		
224	F-toxRup-p7	CTGCGAGGCTGGCCGGCGTCCGTTATCCGAAATGGTCAACGTATTTTGTC
225	R-toxRups	CTCAGTCAGGCATATCTCTTGAGTTGTGCTTAATCC
226	F-toxSdow	GAGATATCGCTGACTGAGCGTAGAATAGGACATAAC
227	R-toxSdow-p7	CAAGCTTATCGATACCGTCGAGTATGCCCGAGCTATGGCGTCTGGAAGGCGATAAC
228		
229	F-BAD-pSW	GGTACCCCGCCGGTGTGCCGCCACGATG
230	F-pSW23-BAD	ACCGGCGGGGTACCGCGCTTTCCGCTGC
231	R-BAD43-oriT	CTGGCCGGCGGCTCACTGCCGCTTCCAGTCGGG
232	R-OriT-BAD43	CAGTGAGCCGCCGGCAGCCTCGCAGAGCA
233		
234	R-PL-ccdA	GATTTCTCATACCGTCTCTGTTACAATAATAACTGTTAC
235	F-PL-plasmid	CTGTTCAAGCCGTATTCTACAAATAAAACTGTAGCC
236	F-ccdA-PL	GACGGTATGAGAAATCAATATAACACAAGCGTAAAG
237	R-ccdA-plasmid	CAGCCTTAAATAACTCGGTATGAATCAGAAAAAGACCGTG
238	F-plasmid-dA	gtattttaAGGCTGTCTATGTGACTGTTGAGC
239	R-plasmid-PL	gggcttGAAACAGGCGATGCTGCTTATCGAATC
240		
241	F-ccdB-SD-OK	CACAAAGGAGGTATTCCATGTCTCAATTACGCTATATAAAAAC
242	R-PU-SD-OK	CATGGAATACCTCCTTGCGACGTAAGCCACGTCAATCG
243	F-PL-O1-B	GCTACAGTTAAACTGTAACAGGAGACGGTATGAGAAATCAATATAACAC
244	R-PL-O1	CTCCTGTTACAGTTAAACtgtAGcaagattgaatgttacagttaaacTG
245	F-PL-SD-T	CAGTTATTATTGTAACAgTagacggatgAGAAATCAATATAACAC
246	R-PL-SD-T	GATTTCTCATACCGTCTACTGTTACAATAATAACTgttacaag
247		
248	F-R6K-weapon	CAAGAGCCATCAATTCCCATGTCAGCCGTTAAGTG
249	R-R6K-weapon	GTAATACTGCGCGTAGAGGGATCTGAAGATCAGCAGTTC
250	F-weapon-R6K	GATCCTCTACGCCGAGTATTACAAAAGGATGTCGCAAACGCTG
251	R-weapon-R6K	GGGAATTGATGGCTTTGTATCTACTGAAGCATC
252		

## REFERENCES

- 253 1. Le Roux F, Binesse J, Saulnier D, Mazel D (2007) Construction of a *Vibrio splendidus*  
254 mutant lacking the metalloprotease gene vsm by use of a novel counterselectable  
255 suicide vector. *Appl Environ Microbiol* 73(3):777–784.
- 256 2. Demarre G, et al. (2005) A new family of mobilizable suicide plasmids based on broad  
257 host range R388 plasmid (IncW) and RP4 plasmid (IncPa) conjugative machineries  
258 and their cognate *Escherichia coli* host strains. *Res Microbiol* 156(2):245–255.
- 259 3. Heidelberg JF, et al. (2000) DNA sequence of both chromosomes of the cholera  
260 pathogen *Vibrio cholerae*. *Nature* 406(6795):477–483.
- 261 4. Val ME, Skovgaard O, Ducos-Galand M, Bland MJ, Mazel D (2012) Genome  
262 engineering in *Vibrio cholerae*: A feasible approach to address biological issues. *PLoS*  
263 *Genet* 8(1). doi:10.1371/journal.pgen.1002472.

- 264 5. Waldor MK, Mekalanos JJ (1994) ToxR regulates virulence gene expression in non-  
265 O1 strains of *Vibrio cholerae* that cause epidemic cholera. *Infect Immun* 62(1):72–78.  
266 6. Guzman LM, Belin D, Carson MJ, Beckwith J (1995) Tight regulation, modulation, and  
267 high-level expression by vectors containing the arabinose P(BAD) promoter. *J  
268 Bacteriol* 177(14):4121–4130.  
269 7. Bartolome B, Jubete Y, Martinez E, de la Cruz F (1991) Construction and properties of  
270 a family of pACYC184-derived cloning vectors compatible with pBR322 and its  
271 derivatives. *Gene* 102(1):75–78.  
272